Emles Venture Partners — 2023 Investments
1 investments dated 2023 · listed companies and verified rows first · show all
Mytos develops automated manufacturing technology for regenerative medicines, specifically targeting the production of stem cell-derived therapies to make treatments for conditions like Parkinson's, blindness, and spinal cord injury accessible and affordable to patients.
Advanced ManufacturingBiotechDeep TechHardwareHealthtechMedical DevicesRoboticsLondon, GB
Ali Afshar(Founder/CEO)inIgnacio Willats(Founder)in
Co-investorsY CombinatorAcequia Capital (AceCap)Artis VenturesDeep Science VenturesIQ CapitalKinled Holding+4 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.